
| Top 5 Drug Type | Count |
|---|---|
| Diagnostic radiopharmaceuticals | 44 |
| Small molecule drug | 27 |
| Radiopharmaceuticals and diagnostic agent | 15 |
| Radionuclide Drug Conjugates (RDC) | 12 |
| Peptide Conjugate Radionuclide | 5 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseNDA/BLA |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism SPECT |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CaM modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date22 Sep 2026 |
Sponsor / Collaborator |
Start Date01 Sep 2026 |
Sponsor / Collaborator |
Start Date01 Sep 2026 |
Sponsor / Collaborator |

| Drug(Targets) | Indications | Global Highest Phase |
|---|---|---|
99mTc N-Isonitrile Glucosamine | Non-Small Cell Lung Cancer More | Phase 2 |
Recombinant human Calcineurin B subunit(Haikou Qili Pharmaceutical) ( CaM ) | Advanced gastric carcinoma More | Phase 1/2 |
99mTcN-Isonitrile glucose | Neoplasms More | Phase 1 |
DA-5 | Vascular Diseases More | Preclinical |
[99mTc]Tc-CNMCHDG | Neoplasms More | Preclinical |





